Suppr超能文献

对甲状腺相关性眼病患者中与“64-kd眼肌蛋白”反应的血清自身抗体患病率的重新评估。

Reevaluation of the prevalences of serum autoantibodies reactive with "64-kd eye muscle proteins" in patients with thyroid-associated ophthalmopathy.

作者信息

Kubota S, Gunji K, Stolarski C, Kennerdell J S, Wall J

机构信息

Department of Ophthalmology, Allegheny General Hospital, and Allegheny University of the Health Sciences, Pittsburgh, Pennsylvania 15212-4772, USA.

出版信息

Thyroid. 1998 Feb;8(2):175-9. doi: 10.1089/thy.1998.8.175.

Abstract

Serum autoantibodies reactive with eye muscle proteins of "64 kilodaltons (kd)" are frequently found in patients with Graves' hyperthyroidism and thyroid-associated ophthalmopathy (TAO). Earlier, we cloned a 64-kd protein that was identified as calsequestrin, a calcium-binding protein localized in the sarcoplasmic reticulum of striated muscle and extensively studied another cloned 64-kd protein, called 1D, which is expressed in thyroid and eye muscle, and some other tissues. Using a monoclonal antibody against calsequestrin, a polyclonal antibody against 1D and a TAO patient serum reactive with the "64-kd protein," as probes, we performed Western blots of porcine eye muscle membrane. We identified three different proteins in the 63 to 67 kd molecular weight range that were targeted by antibodies in sera from patients with TAO. It was not possible to differentiate antibodies reactive with calsequestrin and 1D because these two proteins have very similar molecular weights--63 to 64 kd--and band appearance in Western blotting. A 67-kd protein was most frequently recognized by TAO patients' sera. Serum antibodies reactive with the 67-kd protein were detected in 73% of patients with active TAO of 1 year duration or less, in 37% of patients with TAO of more than 3 years' duration, in 35% with Graves' hyperthyroidism without evident ophthalmopathy, in 30% of patients with Hashimoto's thyroiditis, and in 16% of normal subjects. Serum antibodies reactive with calsequestrin/1D were detected in 47% of patients with active TAO of less than 1 year, in 22% of patients with TAO longer than 3 years, 17% with Graves' hyperthyroidism without evident ophthalmopathy, in 10% of patients with Hashimoto's thyroiditis, and in 21% of normal subjects. The prevalence of anti-67-kd protein antibodies in TAO patients corresponded to those reactive with the so called "64-kd protein" that we have reported previously. In conclusion, we were able to improve the accuracy of the Western blots by comparing the molecular weight of positive bands using specific antibodies reactive with eye muscle antigens as probes. The previously recognized, and extensively studied, "64-kd protein" is now shown to have a molecular weight of 67 kd. The role of the various eye muscle antibodies in the diagnosis and management of the ophthalmopathy associated with Graves' hyperthyroidism needs to be addressed in prospective studies using purified or recombinant full-length proteins.

摘要

在格雷夫斯氏甲状腺功能亢进症(Graves' hyperthyroidism)和甲状腺相关性眼病(TAO)患者中,经常发现与“64千道尔顿(kd)”眼肌蛋白发生反应的血清自身抗体。此前,我们克隆了一种64-kd蛋白,鉴定其为肌集钙蛋白(calsequestrin),一种定位于横纹肌肌浆网的钙结合蛋白,并对另一种克隆的64-kd蛋白(称为1D)进行了广泛研究,该蛋白在甲状腺、眼肌及其他一些组织中表达。我们使用抗肌集钙蛋白的单克隆抗体、抗1D的多克隆抗体以及与“64-kd蛋白”发生反应的TAO患者血清作为探针,对猪眼肌膜进行了蛋白质印迹分析。我们在63至67 kd分子量范围内鉴定出了三种不同的蛋白,它们是TAO患者血清中抗体的靶向目标。由于这两种蛋白分子量非常相似(63至64 kd)且在蛋白质印迹中条带表现相似,因此无法区分与肌集钙蛋白和1D发生反应的抗体。一种67-kd蛋白最常被TAO患者血清识别。在病程1年及以内的活动性TAO患者中,73%检测到与67-kd蛋白发生反应的血清抗体;在病程超过3年的TAO患者中,37%检测到该抗体;在无明显眼病的格雷夫斯氏甲状腺功能亢进症患者中,35%检测到该抗体;在桥本甲状腺炎患者中,30%检测到该抗体;在正常受试者中,16%检测到该抗体。在病程小于1年的活动性TAO患者中,47%检测到与肌集钙蛋白/1D发生反应的血清抗体;在病程超过3年的TAO患者中,22%检测到该抗体;在无明显眼病的格雷夫斯氏甲状腺功能亢进症患者中,17%检测到该抗体;在桥本甲状腺炎患者中,10%检测到该抗体;在正常受试者中,21%检测到该抗体。TAO患者中抗67-kd蛋白抗体的患病率与我们之前报道的与所谓“64-kd蛋白”发生反应的抗体患病率相符。总之,我们通过使用与眼肌抗原发生反应的特异性抗体作为探针,比较阳性条带的分子量,提高了蛋白质印迹分析的准确性。之前被认可并广泛研究的“64-kd蛋白”现在显示其分子量为67 kd。在使用纯化或重组全长蛋白的前瞻性研究中,需要探讨各种眼肌抗体在格雷夫斯氏甲状腺功能亢进症相关眼病诊断和治疗中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验